Search
Search Results
##search.searchResults.foundPlural##
-
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1542PDF: 949HTML: 226 -
PREVALENCE OF HEPATITIS B, HEPATITIS C AND HIV IN MULTIPLY TRANSFUSED SICKLE CELL DISEASE PATIENTS FROM OMAN HBV,HCV and HIV and Sickle Cell Disease.
1630PDF: 992HTML: 361 -
COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES
1115PDF: 487HTML: 8167 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1248PDF: 1000HTML: 211 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2414PDF: 1593HTML: 629 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1971PDF: 754HTML: 696 -
-
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
2766PDF: 1012HTML: 412TABLE: 192FIGURES: 254 -
Allogeneic transplantation in patients with advanced systemic mastocytosis: case report of a single center experience Allogeneic Transplantation in Systemic Mastocytosis
14PDF: 4HTML: 1 -
Parvovirus B19-triggered acute hemolytic anemia and thrombocytopenia in a child with Evans syndrome
3531PDF: 985HTML: 425Table 1.: 226 -
BONE MARROW ABONRMALITIES IN HIV INFECTION
1880PDF: 1135HTML: 1761 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2040PDF: 827HTML: 247 -
SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE COVID-19 and Hematology
1078PDF: 962HTML: 328 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
2525PDF: 1194HTML: 11799 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3392PDF: 1295HTML: 1906Fig.1: 200Fig. 2: 210 -
A strange case of Malaria in a Nigerian native boy.
2448PDF: 861HTML: 1305







